Zobrazeno 1 - 10
of 56
pro vyhledávání: ''
Autor:
Andrey Sivkov, Svetlana Sivkova, Roman V. Gorenkov, Sergey Sivkov, Natalya P. Chernus, Tamara Savina
Publikováno v:
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-9 (2021)
Lipids in Health and Disease
Lipids in Health and Disease
Background To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. Methods The study consists of 180 patients, aged 40–75 yea
Autor:
Jiacheng Lai, Qingtong Wang, Meili Dong, Bin Li, Jingshu Ni, Yikun Wang, Chongjian Huang, Yongsheng Han
Publikováno v:
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-9 (2021)
Lipids in Health and Disease
Lipids in Health and Disease
Background Lipid management is the first line of treatment for decreasing the incidence of cardiovascular events in patients with coronary heart disease (CHD), and a variety of indicators are used to evaluate lipid management. This work analyses the
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-10 (2020)
Lipids in Health and Disease
Lipids in Health and Disease
Background Reduction in elevated serum cholesterol concentrations is important in the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction and thrombotic stroke. Although HMGCoA reductase
Autor:
Suresh Kumar, Priya Kashyap, Rashmi Tripathi, Noopur Jaipal, Abeer Hashem, Baby Tabassum, Heera Ram, Jaykaran Charan, Chandra Nayaka Siddaiah, Bhim Singh, Elsayed Fathi Abd_Allah
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-11 (2020)
Lipids in Health and Disease
Lipids in Health and Disease
BackgroundThe HMG-CoA reductase is key enzyme of cholesterol biosynthesis which potentially contributes in management of hypercholesterolemia. The present study was designed to assess the inhibitory effect of phytoconstituents of an ethanolic extract
Publikováno v:
Lipids in Health and Disease, Vol 18, Iss 1, Pp 1-11 (2019)
Lipids in Health and Disease
Lipids in Health and Disease
BackgroundThe cholesterol gallstones diseases (CGD) is highly correlated with metabolic syndrome and type 2 diabetes. The present study aimed to investigate preventive effects of pioglitazone (PIO), an antidiabetic drug, on the CGD in guinea pigs fed
Autor:
Maria Cristina de Oliveira Izar, Francisco Antonio Helfenstein Fonseca, Ana Paula de Queiroz Mello, Amanda Santoro Fonseca Bacchin, Carolina Nunes França, Antônio Martins Figueiredo Neto, Leticia C. S. Pinto, Flavio T. Moreira, Rui Póvoa, Nágila Raquel Teixeira Damasceno, Adriano Caixeta, Henrique Tria Bianco
Publikováno v:
Lipids in Health and Disease
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-10 (2021)
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-10 (2021)
Background Large observational studies have shown that small, dense LDL subfractions are related to atherosclerotic cardiovascular disease. This study assessed the effects of two highly effective lipid-lowering therapies in the atherogenic subclasses
Publikováno v:
Lipids in Health and Disease, Vol 17, Iss 1, Pp 1-9 (2018)
Lipids in Health and Disease
Lipids in Health and Disease
Background Although there were many studies reporting the combination therapy of Ezetimibe and Atorvastatin’s efficacy and Atorvastatin monotherapy’s, the conclusions were controversial. Therefore, a systematic review and meta analysis of combina
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-7 (2020)
Lipids in Health and Disease
Lipids in Health and Disease
Background The aim of this study was to compare and summarize the lipid-altering effects of combination therapy with ezetimibe and statins (E/S) and a double dose of statin (D/S) monotherapy on patients with hypercholesterolemia. Methods We conducted
Publikováno v:
Lipids in Health and Disease, Vol 17, Iss 1, Pp 1-13 (2018)
Lipids in Health and Disease
Lipids in Health and Disease
Background The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the s
Autor:
Seok Min Kang, Donghoon Choi, Sungha Park, Seungbum Choi, Ji Eun Lee, Kim Kyeong Yeon, Dong Huey Cheon, Hye Min Noh, Sang Hak Lee, Eun Jeong Cheon, Soo jin Ann, Chan Joo Lee
Publikováno v:
Lipids in Health and Disease
Background The influence of lipid-lowering therapy on high-density lipoprotein (HDL) is incompletely understood. We compared the effect of two lipid-lowering strategies on HDL functions and identified some HDL-related proteins. Methods Thirty two pat